Drug updated on 4/17/2024

Dosage FormInjection (intravenous; 100 mg/5 mL, 400 mg/20 mL [20 mg/mL] in a single-dose vial)
Drug ClassEpidermal growth factor receptor antagonists
Ongoing and
Completed Studies


  • Indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC): in combination with FOLFOX for first-line treatment.
  • Indicated as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.

Latest News

loading GIF

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Panitumumab (Vectibix) is indicated for the treatment of wild-type RAS metastatic colorectal cancer, either in combination with FOLFOX for first-line treatment or as monotherapy following disease progression after prior chemotherapy. It has been found to significantly increase objective response rates and R0 resection rates when combined with triplet-drug chemotherapy.
  • Four studies focused on the application of Vectibix in treating metastatic colorectal cancer. These studies highlighted both its effectiveness and safety profile compared to other drugs used for this condition.
  • Common grade 3 and 4 adverse events associated with panitumumab include diarrhea, neutropenia, and skin toxicity. Despite these side effects, it is considered very effective, especially when combined with a regimen like FOLFOXIRI.
  • In terms of efficacy among different patient subgroups, panitumumab shows significant improvement in patients carrying wild-type KRAS gene status but does not affect those with mutant KRAS in terms of objective response or disease progression rate.
  • When comparing fatal adverse events across targeted drugs including bevacizumab, cetuximab, and panitumumab; no significantly increased risks were observed, suggesting a comparable safety profile among these agents. However, a slightly higher risk was noted for cetuximab in adjuvant treatment settings based on relative risks for fatal adverse events.
  • Patients receiving combination therapy involving anti-EGFR agents such as Vectibix might experience higher rates of resection during metastasis, indicating potential benefits related to surgical outcomes while maintaining long-term safety profiles similar to other treatments currently available.